Angiotensin Fragment 1-7 (acetate) |
| رقم الكتالوجGC12671 |
type 1 angiotensin II receptor agonist
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Angiotensin Fragment 1-7 is a type 1 angiotensin II receptor agonist.
In the renin-angiotensin system, angiotensin I is cleaved by angiotensin-converting enzyme to form angiotensin II, which has effects on fluid and electrolyte, as well as homeostasis blood pressure.
In vitro: In a previous study, peripheral atherectomy plaques collected from diabetic (DM) and 12 non-DM patients were immunostained. Results showed that the tissue contents of ACE2, angiotensin fragment 1-7, and AT1R were increased in DM when compared to non-DM. IL-6 and TNF-α were also increased in DM when compared to non-DM, as well as macrophage infiltration score and neovessel counting [1].
In vivo: The effects of chronic angiotensin fragment 1-7 treatment was studied in an experimental model of the metabolic syndrome, rats given high-fructose/low-magnesium diet (HFrD). After 6 months, angiotensin fragment 1-7-treated animals had lower body weight, total fat mass, and serum triglycerides, improved glucose tolerance, and better insulin sensitivity. Similar metabolic effects were also evident, albeit in the absence of weight loss, in rats first exposed to HFrD for 5 months and then subjected to short-term treatment with angiotensin fragment 1-7 [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Purushothaman, K. R.,Krishnan, P.,Purushothaman, M., et al. Expression of angiotensin-converting enzyme 2 and its end product angiotensin 1-7 is increased in diabetic atheroma: Implications for inflammation and neovascularization. Cardiovascular Pathology 22, 42-48 (2013).
[2] Marcus, Y. ,Shefer, G.,Sasson, K., et al. Angiotensin 1-7 as means to prevent the metabolic syndrome: Lessons from the fructose-fed model. Diabetes 62, 1121-1130 (2013).
| Cas No. | SDF | ||
| Chemical Name | 5-L-isoleucine-1-7-angiotensin II | ||
| Canonical SMILES | O=C([C@H](CC1=CNC=N1)NC([C@@]([H])(NC([C@H](CC2=CC=C(C=C2)O)NC([C@@H](NC([C@@H](NC([C@H](CC(O)=O)N)=O)CCCNC(N)=N)=O)C(C)C)=O)=O)[C@H](CC)C)=O)N3CCC[C@H]3C(O)=O.CC(O)=O | ||
| Formula | C41H62N12O11 • XC2H4O2 | M.Wt | 899 |
| الذوبان | ≤10mg/ml in PBS | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1123 mL | 5.5617 mL | 11.1235 mL |
| 5 mM | 0.2225 mL | 1.1123 mL | 2.2247 mL |
| 10 mM | 0.1112 mL | 0.5562 mL | 1.1123 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *